Abstract
Background: Measuring and estimating alcohol consumption (AC) is important for individual health, public health, and Societal benefits. While self-report and diagnostic interviews are commonly used, incorporating biological-based indices can offer a complementary approach. Methods: We evaluate machine learning (ML) based predictions of AC using blood and urine-derived biomarkers. This research has been conducted using the UK Biobank (UKB) Resource. In addition to the prediction of the number of alcoholic Drinks Per Week (DPW), four other related phenotypes were predicted for performance comparison. Five ML models were assessed including LASSO, Ridge regression, Gradient Boosting Machines (GBM), Model Boosting (MBOOST), and Extreme Gradient Boosting (XGBOOST). Results: All five ML methods achieved moderate prediction of DPW (r2=0.304-0.356) with biomarkers significantly increasing prediction above using only known covariates and liver enzymes (r2=0.105). XGBOOST achieved the best prediction performance (r2=0.356, MAE=5.214) at the expense of increasing model complexity and training resources compared to other ML methods. All ML models were able to accurately predict if subjects were heavy drinkers (DPW>8 for women and DPW>15 for men) and produced explainable models that highlighted the role of biomarkers in predicting DPW. While phenotype correlations were similar across methods, XGBOOST produced similar heritability estimates for observed (h2=0.064) and predicted (h2=0.077) DPW. The estimated genetic correlation between observed and predicted DPW was 0.877. Conclusions: Predicting AC from ML-based biological measures provides an opportunity to identify individuals at increased risk of heavy AC, thereby offering complementary avenue for risk assessment beyond self-report, screening instruments, or structured interviews, which have some known biases. In addition, explainable AI tools identified a constellation of biomarkers associated with AC.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research has been conducted using the UK Biobank Resource application number 30782. MH, REP, BTW, and AEG were supported by NIH P50AA022537, REP, BTW, and AEG by NIH R01MH125938, REP by The Brain & Behavior Research Foundation NARSAD grant 28632 P&S Fund, AEG by NIH 1K01AA031748-01 and ECP by 1R01DA054313-01A1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research has been conducted using the UK Biobank Resource application number 30782.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
